<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d115">
    <sentence id="DDI-DrugBank.d115.s0" text="Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).">
        <entity id="DDI-DrugBank.d115.s0.e0" charOffset="21-28"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s0.e1" charOffset="76-83"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s0.e2" charOffset="150-156"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s0.e3" charOffset="202-213"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d115.s0.e4" charOffset="216-227"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d115.s0.e5" charOffset="230-241"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d115.s0.e6" charOffset="244-257"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d115.s0.d0" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d1" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d2" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d3" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s1" text="Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.">
        <entity id="DDI-DrugBank.d115.s1.e0" charOffset="109-116"
            type="drug" text="imatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s2" text="There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).">
        <entity id="DDI-DrugBank.d115.s2.e0" charOffset="47-54"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s2.e1" charOffset="61-67"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s2.e2" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d115.s2.d0" e1="DDI-DrugBank.d115.s2.e1"
            e2="DDI-DrugBank.d115.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s3" text="Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.">
        <entity id="DDI-DrugBank.d115.s3.e0" charOffset="24-31"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s3.e1" charOffset="141-148"
            type="drug" text="imatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s4" text="Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.">
        <entity id="DDI-DrugBank.d115.s4.e0" charOffset="41-53"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d115.s4.e1" charOffset="56-64"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d115.s4.e2" charOffset="67-79"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d115.s4.e3" charOffset="82-89"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d115.s4.e4" charOffset="92-104"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s5" text="Johns Wort) may significantly reduce exposure to Gleevec.">
        <entity id="DDI-DrugBank.d115.s5.e0" charOffset="49-55"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s6" text="Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).">
        <entity id="DDI-DrugBank.d115.s6.e0" charOffset="58-65"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d115.s6.e1" charOffset="96-102"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s6.e2" charOffset="115-121"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s6.d0" e1="DDI-DrugBank.d115.s6.e0"
            e2="DDI-DrugBank.d115.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s7" text="In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.">
        <entity id="DDI-DrugBank.d115.s7.e0" charOffset="18-25"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s8" text="Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.">
        <entity id="DDI-DrugBank.d115.s8.e0" charOffset="58-64"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s8.e1" charOffset="66-72"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s8.e2" charOffset="109-119"
            type="drug" text="simvastatin"/>
        <entity id="DDI-DrugBank.d115.s8.e3" charOffset="213-219"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s8.d0" e1="DDI-DrugBank.d115.s8.e1"
            e2="DDI-DrugBank.d115.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s9" text="Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).">
        <entity id="DDI-DrugBank.d115.s9.e0" charOffset="53-59"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s9.e1" charOffset="129-140"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d115.s9.e2" charOffset="145-152"
            type="drug" text="pimozide"/>
        <ddi id="DDI-DrugBank.d115.s9.d0" e1="DDI-DrugBank.d115.s9.e0"
            e2="DDI-DrugBank.d115.s9.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s9.d1" e1="DDI-DrugBank.d115.s9.e0"
            e2="DDI-DrugBank.d115.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s10" text="Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).">
        <entity id="DDI-DrugBank.d115.s10.e0" charOffset="0-6"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s10.e1" charOffset="92-106"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d115.s10.e2" charOffset="109-148"
            type="group" text="dihydropyridine calcium channel blockers"/>
        <entity id="DDI-DrugBank.d115.s10.e3" charOffset="159-186"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <ddi id="DDI-DrugBank.d115.s10.d0" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d115.s10.d1" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d115.s10.d2" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s11" text="Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.">
        <entity id="DDI-DrugBank.d115.s11.e0" charOffset="8-15"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d115.s11.e1" charOffset="139-145"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s12" text="in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity.">
        <entity id="DDI-DrugBank.d115.s12.e0" charOffset="10-16"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s13" text="Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec."/>
    <sentence id="DDI-DrugBank.d115.s14" text="No specific studies have been performed and caution is recommended."/>
    <sentence id="DDI-DrugBank.d115.s15" text="in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5  M) at therapeutic levels.">
        <entity id="DDI-DrugBank.d115.s15.e0" charOffset="10-16"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s16" text="Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.">
        <entity id="DDI-DrugBank.d115.s16.e0" charOffset="21-33"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d115.s16.e1" charOffset="88-94"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s16.d0" e1="DDI-DrugBank.d115.s16.e0"
            e2="DDI-DrugBank.d115.s16.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s17" text="No specific studies in humans have been performed and caution is recommended."/>
    <sentence id="DDI-DrugBank.d115.s18" text=""/>
</document>
